Rankings / Metabolic Health

Elecoglipron (AZD5004 / ECC5004)

Metabolic Health · Oral small-molecule GLP-1 agonist

Tier C+

Reviewed by Read Off Label · Last reviewed · How we grade

incretinglp1-agonistoral-glp1investigationalweight-loss
5.7 / 10
Tier C+
Ev 6 Bn 6.5 Sf 5

Bottom line

Read Off Label grades Elecoglipron (AZD5004 / ECC5004) as C+ (5.7/10) based on moderate evidence, moderate-high benefit magnitude, and a med-risk safety profile.

AstraZeneca's oral GLP-1 pill (in-licensed from Eccogene in 2023; AZD5004 / ECC5004) — a direct competitor to Lilly's orforglipron in the race for a convenient oral incretin.

Typical use: Oral once daily — Investigational.

What this is

AstraZeneca's oral GLP-1 pill (in-licensed from Eccogene in 2023; AZD5004 / ECC5004) — a direct competitor to Lilly's orforglipron in the race for a convenient oral incretin. Phase 2 VISTA (n=310, 36 wk, obesity/overweight) and SOLSTICE (n=406, type 2 diabetes) both met their primary endpoints and AstraZeneca is advancing it to Phase 3; multiple datasets were presented at ADA 2026, though exact weight-loss figures were initially held back. Industry-sponsored; peer-reviewed publication pending.

Mechanism

Once-daily oral non-peptide GLP-1 receptor agonist — delivers incretin appetite suppression and glycemic control as a pill rather than an injection

Dose & route

Oral once daily

Citations

Links go to the source. If a link is dead or you want something re-checked, let me know.

Common questions

Does Elecoglipron (AZD5004 / ECC5004) work?
Read Off Label rates the evidence for Elecoglipron (AZD5004 / ECC5004) as Moderate and the benefit magnitude as moderate-high, producing an overall grade of C+ (5.7/10). AstraZeneca's oral GLP-1 pill (in-licensed from Eccogene in 2023; AZD5004 / ECC5004) — a direct competitor to Lilly's orforglipron in the race for a convenient oral incretin.
Is Elecoglipron (AZD5004 / ECC5004) safe?
Elecoglipron (AZD5004 / ECC5004) has a med risk profile in published human data. Legal status: Investigational (Phase 2 complete; advancing to Phase 3). This is not medical advice — see the disclaimer.
What is the typical dose for Elecoglipron (AZD5004 / ECC5004)?
Oral once daily
How does Elecoglipron (AZD5004 / ECC5004) work?
Once-daily oral non-peptide GLP-1 receptor agonist — delivers incretin appetite suppression and glycemic control as a pill rather than an injection

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.